Hoth Therapeutics, Inc. (HOTH)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net revenues | - | - | - | - |
| Research and development expenses | 1,039,713 | 1,958,602 | 897,510 | 566,335 |
| General and administrative expenses | 1,159,936 | 1,517,415 | 1,234,743 | 1,079,504 |
| Total operating expenses | 2,199,649 | 3,476,017 | 2,132,253 | 1,645,839 |
| Loss from operations | -2,199,649 | -3,476,017 | -2,132,253 | -1,645,839 |
| Dividend and interest income | 173 | 181 | 200 | 13,365 |
| Change in fair value of investment in joint ventures | - | - | - | - |
| Total other income, net | 173 | 181 | 200 | 13,365 |
| Net loss | -2,199,476 | -3,475,836 | -2,132,053 | -1,632,474 |
| Foreign currency translation adjustment | 3,478 | -497 | 2,490 | 1,634 |
| Total comprehensive loss | -2,195,998 | -3,476,333 | -2,129,563 | -1,630,840 |
| Basic (in dollars per share) | -0.17 | -0.27 | -0.31 | -0.24 |
| Basic (in shares) | 13,180,243 | 12,727,581 | 6,903,804 | 6,876,331 |
| Net loss per common share, diluted (in dollars per share) | -0.17 | -0.27 | -0.31 | -0.24 |
| Weighted average number of common shares outstanding, diluted (in shares) | 13,180,243 | 12,727,581 | 6,903,804 | 6,876,331 |